Chenodeoxycholic acid , Analysis standard , 474-25-9

Synonym(s):
3α,7α-Dihydroxy-5β-cholanic acid;5β-Cholanic acid-3α,7α-diol;Chenodiol

CAS NO.：474-25-9

Empirical Formula: C24H40O4

Molecular Weight: 392.57

MDL number: MFCD00064142

EINECS: 207-481-8

PRODUCT Properties

• Melting point: 165-167 °C (lit.)
• Boiling point: 437.26°C (rough estimate)
• alpha: 12 º (c=1, CHCl3)
• Density: 0.9985 (rough estimate)
• refractive index: 1.4460 (estimate)
• Flash point: 9℃
• storage temp.: room temp
• solubility: PRACTICALLY INSOLUBLE
• form: Powder
• pka: pKa 4.34 (Uncertain)
• color: White to off-white
• Water Solubility: PRACTICALLY INSOLUBLE
• Merck: 13,2062
• BRN: 3219887
• InChIKey: RUDATBOHQWOJDD-BSWAIDMHSA-N
• LogP: 3.05 at 20℃

Description and Uses

Chenodeoxycholic acid is the first agent to be introduced into the US market for the treatment of radiolucent gallstones. Large scale clinical trials have demonstrated the safety and efficacy of this agent. Chenodeoxycholic acid reduces the biliary concentration of cholesterol relative to that of bile acids and phospholipid, reducing the saturation and thus the lithogenicity of the bile. Success rates in dissolving gallstones are in the range of 50-70% within 4-24 months of treatment. Continuation of the drug after stone dissolution may be required to prevent reoccurrence. Chenodeoxycholic acid is the 7α-isomer of ursodeoxycholic acid which was introduced into the European market in 1978.

chenodeoxycholic acid structure

An apoptosis inducer via PKC-dependent signalling pathway.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319
• Precautionary statements: P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313
• Hazard Codes: Xn
• Risk Statements: 63
• Safety Statements: 22-24/25-45-36/37
• RIDADR: UN1230 - class 3 - PG 2 - Methanol, solution
• WGK Germany: 2
• RTECS: FZ1980000
• HS Code: 29181990